Barriers to accrual and enrollment in brain tumor trials
Barriers to accrual and enrollment in brain tumor trials
复制标题
DOI：
10.1093/neuonc/noz104
复制
发表时间：
2019-09-01
期刊：
影响因子：
15.9
通讯作者：
Wen, Patrick Y.
中科院分区：
文献类型：
--
作者：
Lee, Eudocia Q.;Chukwueke, Ugonma N.;Wen, Patrick Y.
导致恶性脑瘤患者存活率低的因素很多，其中一些因素很难治愈。然而，缺乏进展的一个可能是可修改的因素是临床试验收益不佳。对脑瘤患者和神经肿瘤学提供者的调查表明，临床医生在与患者讨论临床试验和转介患者进行临床试验方面做得很差。然而，来自美国癌症协会癌症行动网络的数据表明，大多数被要求参加临床试验的符合条件的肿瘤学患者都会同意这样做。为此，神经肿瘤学会(SNO)与神经肿瘤反应评估(RANO)工作组、患者权益团体、临床试验合作团体(包括成人脑瘤联合会(ABTC))和其他合作伙伴正在共同努力，意图在未来5年内将临床试验收益增加一倍。在这里，我们描述了导致神经肿瘤学临床试验收益不佳的因素，并提供了可能的解决方案。
Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.